Guska
PrivateLast Round
Seed
Feb 28, 2024
Total Funding Raised
$750,000
Momentum Score
25 /100
Company Overview
Guska is a biotechnology company developing oncolytic virus-based cancer therapies using AI and synthetic biology to engineer RNA viruses that selectively destroy tumor cells.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Guska Comps
Public and private peers based on sector, stage, and business model.
Guska Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Feb 28, 2024 |
Guska Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ficus Capital | Seed |
| LAB+ Company Builder | Seed |
| Institut Pasteur de Montevideo | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 1, 2026
Monthly visitors grew 73% MoM.
- Aug 22, 2025
Grew 43% QoQ from 7 to 10 employees.
Guska Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Guska's valuation, stock price, and market status.
